Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients with Asthma

CPT: Pharmacometrics and Systems Pharmacology

Volumn 6, Issue 4, 2017, Pages 249-257

  Wang, B ^a   Yan, L ^a   Yao, Z ^a,b   Roskos, L K ^a  

^a MEDIMMUNE   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BENRALIZUMAB; IMMUNOGLOBULIN G; ANTIASTHMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; ASTHMA; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RESPONSE; EC50; EOSINOPHIL COUNT; FEMALE; HALF LIFE TIME; HUMAN; IMMUNOASSAY; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; DOSE RESPONSE; DRUG EFFECTS; EOSINOPHIL; MARKOV CHAIN; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NORMAL HUMAN; YOUNG ADULT;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHILS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOGLOBULIN G; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; STOCHASTIC PROCESSES; YOUNG ADULT;

EID: 85018510445     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12160     Document Type: Article

References (32)

1. Takatsu, K., Takaki, S. & Hitoshi, Y. Interleukin-5 and its receptor system: implications in the immune system and inflammation. Adv. Immunol. 57, 145-190 (1994).
2. Molfino, N.A., Gossage, D., Kolbeck, R., Parker, J.M. & Geba, G.P. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin. Exp. Allergy 42, 712-737 (2012).
3. Ochensberger, B., Tassera, L., Bifrare, D., Rihs, S. & Dahinden C.A. Regulation of cytokine expression and leukotriene formation in human basophils by growth factors, chemokines and chemotactic agonists. Eur. J. Immunol. 29, 11-22 (1999).
4. Murata, Y., Takai, S., Migita, M., Kikuchi, Y., Tominaga, A. & Takatsu, K. Molecular cloning and expression of the human interleukin 5 receptor. J. Exp. Med. 175, 341-351 (1992).
5. Migita, M. et al. Characterization of the human IL-5 receptors on eosinophils. Cell Immunol. 133, 484-497 (1991).
6. Walsh, G.M., Sexton, D.W. & Blaylock, M.G. Corticosteroids, eosinophils and bronchial epithelial cells: new insights into the resolution of inflammation in asthma. J. Endo-crinol. 178, 37-43 (2003).
7. Ilmarinen, P. & Kankaanranta, H. Eosinophil apoptosis as a therapeutic target in allergic asthma. Basic Clin. Pharmacol. Toxicol. 114, 109-117 (2014).
8. Mukherjee, M., Sehmi, R. & Nair, P. Anti-IL5 therapy for asthma and beyond. World Allergy Organ. J. 7, 32 (2014).
9. Koike, M. et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum. Antibodies 18, 17-27 (2009).
10. Kolbeck, R. et al. MEDI-563, a humanized anti-IL-5 receptor a mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J. Allergy Clin. Immunol. 125, 1344-1353 (2010).
11. Busse, W.W. et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL 5 receptor a antibody, in a phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 125, 1237-1244 (2010).
12. Efficacy and safety study of benralizumab in adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting b2 agonist. (2016). Accessed 13 April 2016.
13. Zhang, L., Beal, S.L. & Sheiner, L.B. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J. Pharmacokinet. Pharmacodyn. 30, 387-404 (2003).
14. Harker, L.A. et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95, 2514-2522 (2000).
15. Wang, B. et al. Pharmacokinetic and pharmacodynamics comparability study of mox-etumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys. J. Pharm. Sci. 102, 250-261 (2013).
16. Dansirikul, C., Silber, H.E. & Karlsson, M.O. Approaches to handling pharmacody-namic baseline responses. J. Pharmacokinet. Pharmacodyn. 35, 269-283 (2008).
17. Ahn, J.E., Karlsson, M.O., Dunne, A. & Ludden, T.M. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J. Pharmacokinet. Pharmacodyn. 35, 401-421 (2008).
18. Krzyzanski, W. Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. J. Pharmacokinet. Pharmacodyn. 38, 179-204 (2011).
19. Dale, D.C., Hubert, R.T. & Fauci, A. Eosinophil kinetics in the hypereosinophilic syndrome. J. Lab. Clin. Med. 87, 487-495 (1976).
20. Castro, M. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3, 355-366 (2015).
21. Castro, M. et al. Benralizumab, an anti-interleukin 5 receptor a monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir. Med. 2, 879-890 (2014).
22. Ortega, H.G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198-1207 (2014).
23. Bauer, R.J., Dedrick, R.L., White, M.L., Murray, M.J. & Garovoy, M.R. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J. Pharmacokinet. Biopharm. 27, 397-420 (1999).
24. Hayashi, N., Tsukamoto, Y., Sallas, W.M. & Lowe, P.J. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br. J. Clin. Pharmacol. 63, 548-561 (2007).
25. Wang, B. et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon - A receptor antibody. Clin. Pharmacol. Ther. 93, 483-492 (2013).
26. Wang, B. et al. Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis. J. Clin. Pharmacol. 52, 1150-1161 (2012).
27. Mager, D.E. & Jusko, W.J. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28, 507-532 (2001).
28. Dirks, N.L. & Meibohm, B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 633-659 (2010).
29. Lobo, E.D., Hansen, R.J. & Balthasar, J.P. Antibody pharmacokinetics and pharmaco-dynamics. J. Pharm. Sci. 93, 2645-2668 (2004).
30. Kita, H. & Bochner, B.S. Biology of eosinophils. In Allergy Principles and Practice. 5th edn. 242-260 (Mosby, St. Louis, MO, 1998).
31. Wang, B., et al. Exposure-response analysis for determination of benralizumab optimal dosing regimens in adults with asthma. Am. J. Respir. Crit. Care Med. 189, A1324 (2014).
32. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. (2014). Accessed 13 April 2016.